OXGENE’s novel mammalian antibody display technology targets challenging membrane proteins and facilitates downstream antibody manufacturing
Antibody at the edge of impossible
Our proprietary mammalian antibody discovery platform breaks new ground in the identification of novel molecules to treat the industry’s most challenging diseases. This approach offers a number of advantages over competing systems. We remove the need for protein target purification because we express the target in its native configuration, including correct glycosylation, within the membrane of a mammalian cell.
Our system means we know that any antibody we discover is expressible within a mammalian system, which avoids the need for antibody humanisation and affords significant developability advantages. We couple our platform with our industry leading LEGO-like SnapFast™ plasmid technology to facilitate subsequent antibody engineering and production steps, and so the complete solution from discovery to manufacture.
While our next-generation technologies don’t require humanisation, we recognize that other methods, such as phage display and mouse immunization do, and remain well-established in the field. We therefore offer a bioinformatics-led approach to find the closest possible human-to-animal match.